Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nordic's $62m IPO reheats anti-CD37 cancer therapies

This article was originally published in Scrip

Executive Summary

In the biggest life science initial public offering on a European exchange since November 2014, Nordic Nanovector grossed NOK 500m ($62.3m) from its IPO on the Oslo stock exchange on 23 March 2015. The company raised 20% more than it had originally planned, allowing it now to reach comfortably beyond the first regulatory submission for its lead product Betalutin (177Lu-tetulomab) in non-Hodgkin's lymphoma (NHL). The IPO also potentially breathes new life into an old blood cancer target, CD37.

Advertisement

Related Content

Popular Nordic Nanovector Private Placement To Fund Pipeline Progress

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC028216

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel